

NEWS letter

M_HH

Medizinische Hochschule
Hannover



Graduate School of Excellence

OKTOBER
2023
Alumni



Dear HBRS Alumni,

We proudly present our **18th HBRS Alumni newsletter**.

MHH is currently in a phase of substantial transition, reflected by successful as well as ongoing replacements of many clinic and institute heads due to a retirement wave. HBRS welcomes all of them and looks forward to enroll their PhD and medical doctorate students and, of course, is happy to continue in supporting all our national and international students in all clinics, departments, and institutes of MHH and its partners.

In this newsletter, we give an overview of our current activities as well as news and insights from your fellow Alumni. Thank you for your interest in our work and for your continuous support.

Reinhold Förster, Acting Dean of HBRS

Current status of HBRS and news

HBRS currently comprises six international (MD)/PhD programs ("Molecular Medicine", "Infection Biology / DEWIN", "Regenerative Sciences", "Auditory Sciences", "Epidemiology" and "Biomedical Data Science"). There are meanwhile altogether three structured doctoral programs for medical students to receive the Dr.med. degree (StrucMed; KlinStrucMed and DigiStrucMed).

Three HBRS-associated **Master** programs "Biomedicine", "Biochemistry" and "Biomedical Data Science" are established.

Fritz Hartmann Lecture

Opening of study year, October 2022



Christian Drosten, Director Institute of Virology, Charité Berlin (right) with Reinhold Förster, HBRS (left)

NEWS from professors and supervisors:

- Prof. Moritz Schmelzle became head of the Department for General, Visceral and Transplant Surgery in October 2022.
- Prof. Nataliya Di Donato is now head of the Human Genetics department (succession of Prof. Brigitte Schlegelberger)
- Prof. Kai Schmidt-Ott has become head of the Nephrology department (succession of Prof. Hermann Haller)
- Prof. Andreas Kispert is now head of the Molecular Biology department (succession of Prof. Achim Gossler)

Currently, the various programs of HBRS host ~250 PhD students. In addition, 25 medical students were accepted for StrucMed, 14 for KlinStrucMed and 10 for DigiStrucMed this year. About 80 new Master students (in three programs) are enrolled. About 60% of our PhD students are international and around 10% have a medical background. About 50% are women.

Since 2023, HBRS has been embedded in the newly established Deanery of Academic Career Development lead by Prof. Dr. Anette Melk.

- Prof. Florian Heidel was appointed head of the Hematology, Hämostaseology, Oncology and Stem cell Transplantation department (succession of Prof. Arnold Ganser)
- Prof. Arjang Ruhparwar is the new head of the HTTG surgery (succession of Prof. Axel Haverich).
- Prof. Maximilian Lenz is new head of the Institute for Neuroanatomy and Cell Biology.
- Prof. Gerard Krause (Epidemiology, HZI) moved to the WHO in Genève, Switzerland. He will keep a guest scientist status at MHH.
- Prof. Adrian Schwarzer was appointed CCC-MV professor for Translational and Experimental Oncology in Greifswald.
- Dr. Bernd Heinrich (Gastroenterology) received the prestigious Max Eder stipend for his research on liver carcinoma (HCC).

Guided tour through Hannover, October 2022



Weekend workshop in Berlin

Susanne Kruse and 20 international HBRS students travelled to Berlin from June 30th–July 2nd, 2023. Students from 14 different countries formed part of the group. In the mornings, the trainer Grit Kümmele discussed various aspects of integration into the German thinking and way of life as well as conflict management. The cultural program in the afternoons and evenings included a guided bus tour, a guided tour through the Reichstag, as well as a walking tour to Eastside Gallery. The DAAD kindly supported a weekend workshop for specialists from third world countries on the topic "Understanding the Germans – Intercultural aspects". The weekend was a great success. The workshop will certainly be repeated :-).



News from MHH

Overall MHH received the record sum of 101.4 million Euro of third-party funds in 2022.

Researchers of the department Experimental Hematology and Fraunhofer ITEM received 1.5 million Euro for the project iGUARD. The aim is to develop RNA-based therapies.

The DFG Research Group FOR2953 "Sialic acids as regulators of development and immunity" (speaker PD Dr. Martina Mühlenhoff, Clinical Biochemistry) received 4.6 million Euro for the next three years.

Prof. Nico Lachmann (Pediatric Pneumology) received 2.5 million Euro of the Fraunhofer Attract program for 5 years. He aims to scale up the production of matured immune cells.

Building activities have started for the new Centre for Individualized Medicine (CiIM). It is located right next to Twincore building in Feodor Lynen Strasse.

Else Kröner Fresenius Foundation is supporting the new Medical Scientist program nextGENERATION with 1 million Euro. Speakers are Prof. Nico Lachmann, Prof. Christine Happle as well as Prof. Robert Zweigert.

MHH and partner institutes are currently developing chip-based methods to replace or supplement animal experiments. The R2N project is supported with 3.6 million Euro from EU funds.

ZIB Retreat 2023

Report from the Students' Organization Committee

The Hannover Medical School and the ZIB program recently played host to a remarkable scientific retreat that brought together PhD students and other brilliant minds from Immunology, Microbiology and

Virology. Organizing this ZIB 2023 summer retreat was nothing but an amazing experience for all of us. It took the dedication and the collaborative effort of the entire team and we are thrilled to share the outstanding outcomes and profound impact it had on fostering collaboration and innovation.

The planning process started a year prior with an enthusiastic brainstorming session, where ideas for the perfect retreat experience were shared setting the foundation on which we looked back at every step on the way. The organizing committee divided their responsibilities, with each member overseeing specific aspects of the event, such as inviting speakers, connecting with companies for their sponsorship, building the retreat booklet, scheduling the event and most importantly dealing with MHH. A well-defined schedule was created to give a chance to all students to present their data to others and get feedback.

As the day of the retreat approached, excitement and anticipation filled the air. Upon arrival at the serene venue, participants were greeted with warm smiles and a sense of unity. The opening ceremony set the tone for the retreat, emphasizing the value of collaboration and personal growth within the organization. As our first guest we were able to great Prof. Dr. John Ziebuhr with new intel about RNA structures and enzymes involved in alphacoronavirus RNA synthesis and processing. After him the PhD students of the virology department presented new insights of their own research, reaching from human cytomegalovirus to SARS-CoV-2 and a lot of new inspiration was given through various interested questions.

After some trepidation thanks to Deutsche Bahn, we were also able to welcome our second guest speaker in the afternoon. Niklas Björkström from the Karolinska Institute in Stockholm opened the Immunology session with his exciting talk about the differentiation, tissue-residency and recirculation patterns of human natural killer cells. Following this talk, the PhD students from the Immunology department excitingly presented the topics of their past years of research.

This thrilling and eventful first day was concluded with the speakers' dinner, at which the organizing committee met with the guest speakers and the representatives of two companies. The evening ended with a lot of good food, many laughter as well as funny and informative conversations, as we were already looking forward to the day ahead.



ZIB Organization Team

The second day was introduced by the third guest speaker, Nelson Gekara from the University Medical Center Freiburg and his interesting insights to the role of intracellular DNA sensors in innate immune priming and genome stability. Further, we gained new knowledge about

a broad range of microbial topics through the dedicated presentations of the PhD students from the microbiology departments.

After the lunch break, we were able to welcome further guests from different companies for our career session, to inspire our career possibilities with their experiences. Afterwards, they were available at various stands to answer our questions about different products and methods as well as to give us helpful career tips. At the same time, the younger PhD students had the opportunity to present their work through posters. PhD students and supervisors got into lively conversation and many inspiring discussions brought about new insights, approaches and cooperation talks. The lively conversations and discussions were thus slowly shifted to the „living room“ of the Asta, where a fabulous catering was already waiting. There were many more hours of enthusiastic discussion, laughter and eating as the event slowly drew to a close.

Thus, two very exciting and eventful days came to an end, which we as the organization committee look back on with satisfaction. We have gained many new insights into various topics and are already looking forward to next year and new exciting topics.

The organization committee

News in Research

In this section, we will regularly publish short reviews of important and recent achievements in selected research fields, or useful tips! Everybody is welcome to contribute.

Novel strategy to reduce the immunogenicity of adeno-associated virus (AAV) vectors

by Martin Bentler, Institute of Experimental Hematology, MHH



Alumnus of MD/PhD program
Molecular Medicine; now Postdoc

my name is Martin Bentler and I graduated from the MD/PhD program Molecular Medicine in November 2022. I performed my PhD under the supervision of Prof. Hildegard Büning in the Institute of Experimental Hematology. The research work in the institute strongly focuses on developing novel approaches for cell and gene therapy. The research group of Hildegard Büning focuses on optimizing adeno-associated virus (AAV) vectors for applications in gene therapy. AAV vectors are the most commonly used tools for in vivo gene therapy and six market approvals in Europe for AAV vector-based gene therapy products for spinal muscular atrophy type I, RPE65 gene defect causing retinal diseases and hemophilia A and B (among others) underline its vast potential for clinical use. More gene therapies using AAV vectors are expected to receive market approval considering the large number of advanced-stage clinical trials. However, immune responses toward the AAV vector capsids or vector-encoded transgene products pose a major challenge to the success of AAV vector-directed human gene therapies. Aiming to interfere with the induction of de novo immune responses, we developed a strategy to reduce the innate immune recognition of AAV vectors. Specifically, we inserted a

peptide known to block the Toll-like receptor (TLR) adaptor molecule MyD88 (myeloid differentiation primary response 88) in the AAV2 vector capsid via capsid engineering. The novel capsid variant, AAV2.MB453, displays the MyD88-blocking peptide in a prominent capsid position, the highest peak of the capsid, where the peptide folds into helical structures protruding from the capsid (Figure 1A). Furthermore, the binding of AAV2.MB453 to its target molecule, MyD88, was predicted. The novel capsid variant demonstrated enhanced transduction efficiency in primary human cells, including monocyte-derived dendritic cells (moDCs) and primary human hepatocyte (PHH) cultures (Figure 1B-C). Compared to AAV2 and another capsid-engineered variant, AAV2.VSSTSPR, developed for transducing DC, the novel AAV2.MB453 variant, triggered a reduced innate immune response in moDCs assessed by measuring the expression levels of prime proinflammatory cytokines and chemokines including IL1A, IL1B, IL8 and type I interferons. Moreover, using the intravenous and intramuscular route of administration, we compared adaptive immune responses elicited in mice toward either the parental AAV2 or AAV2.MB453. Mice injected with AAV2.MB453 demonstrated a delayed generation of anti-AAV2 IgG2a binding antibodies compared with AAV2 for both administration routes (Figure 2A-B). Cytotoxic CD8+ T cell responses have been observed in human clinical trials using AAV vectors and are considered capable of lowering the therapeutic benefit of the gene therapy by eliminating AAV vector-transduced target cells. CD8+ T cell responses might be directed toward the AAV capsid or the transgene product. ELISpot analyses revealed reduced levels of anti-transgene CD8+ T cell responses in cohorts administered with AAV2.MB453 after intravenous as well as after intramuscular injection (Figure 2C). At an early time point after intramuscular administration of the vectors, a reduced CD8+ T cell response toward the AAV capsid was also observed for AAV2.MB453-treated compared to AAV2-injected mice (Figure 2D). In summary, we have developed a capsid-engineered AAV2 capsid variant that mitigates innate and adaptive immune responses toward AAV vectors. Our novel strategy might add to the ongoing developments of more efficient and safer AAV vectors for human gene therapy. Combining our capsid-engineered variant with recently published strategies to interfere with AAV-induced immune responses including the addition of a TLR9 inhibitory sequence to the vector transgene is the focus of future studies. Overall, our research has led to the generation of a novel AAV capsid variant that holds promise for further developing improved vectors for AAV-mediated gene therapies.




Figure 1: Modulation of the AAV2. MB453 capsid variant and transgene expression in moDCs.

The MyD88-derived peptide was inserted at I-453 (highest of three protrusions) in the AAV2 capsid (A). Three VP3 capsid subunits are depicted (white, dark gray, and light gray). The highest capsid peak is illustrated in green and the inserted peptide is shown in orange (A). Human moDCs were incubated with indicated vectors at a GOI of 2.5 x 104. To determine the level of vector transgene expression, cells were analyzed via flow cytometry 48 h p.t. (A, B). Mean with individual donors is depicted in (A) and normalized transduction levels as fold change in (B) for n = 5 donors with technical triplicates. Mann-Whitney U test was applied to calculate statistical significance. *p < 0.05. Adapted from Bentler et al., Modifying immune responses to adeno-associated virus vectors by capsid engineering, Mol Ther Methods Clin Dev (2023). Copyright © Bentler et al., an open access article under the CC BY-NC-ND 4.0 license.




Figure 2: Reduced adaptive immune responses in vivo with AAV2.MB453.

BALB/c mice were injected intravenously (A, C) or intramuscularly (B, D) with either 1 x 1011 vg/mouse (A, C, D) or 1 x 1010 vg/mouse (B) of either AAV2 or AAV2.MB453 encoding eGFP as transgenes. Serum was analyzed regarding AAV2-binding antibodies of the IgG2a subtype by ELISA after intravenous (A) and intramuscular (B) administration. Isolated splenocytes were stimulated with immunodominant epitopes for transgene (eGFP; HYLSTQSAL) and AAV2 capsid (QYGSVSTNL + PQYGYLTL), respectively, and antigen-specific, IFN-γ-secreting T cells were counted. T cells reactive to eGFP after intravenous injection (C) and to AAV2 capsid after intramuscular injection (D) are depicted. Data are presented as mean ± SEM for n = 7 mice. Mann-Whitney U test was applied to calculate statistical significance. *p < 0.05; **p < 0.01. Adapted from Bentler et al., Modifying immune responses to adeno-associated virus vectors by capsid engineering, Mol Ther Methods Clin Dev (2023). Copyright © Bentler et al., an open access article under the CC BY-NC-ND 4.0 license.

View from abroad 1 By Marie-Madlen Pust

In this section, we will regularly publish short reports of experiences of our Alumni students as Postdocs etc. abroad! Everybody is welcome to contribute.



Hello from Boston, USA

I finished my PhD in Microbial Ecology and Computational Biology in the Department of Pediatric Pneumology in January 2022, under the guidance of Prof. Dr. Dr. Burkhard Tümmler. By May, I started my postdoctoral appointment as computational research fellow in Boston.

PhD program "Infection Biology"; final exam January 2022; currently Postdoc = computational research fellow at MIT Harvard, Boston

From Hannover's Quiet to Boston's Bustle: As I moved from the familiar halls of MHH to the esteemed corridors of the MIT-Harvard universe,

I found myself stepping out of the cocoon of a PhD student within the tight-knit HBRS community into Boston's vast academic maze. The reassurance of milestone meetings, the routine hunt for signatures following lectures, and the close guidance from our program coordinators and supervisors gave way to a vast, anonymous network of high-achieving professionals recognized globally for their expertise. I suddenly found myself amidst peers who had excelled academically and garnered prestigious publications or awards. The responsibility now rested on my shoulders to generate innovative, competitive ideas, develop them independently, while building a network for collaboration and support. I experienced a roller coaster of emotions. Initially overwhelmed, I soon became excited about the resources available to advance my field of interest. My spirits dropped when I reached the phase where I revisited my PhD projects, contemplating what else could have been achieved if I had had these resources earlier. Optimism returned as I considered leveraging these assets for my up-coming work, but it waned again at the thought that returning to Europe after several years would likely mean stepping back from this level of opportunity and resources again.

MIT, Harvard, Broad: The Triple Helix of Opportunities: After navigating the initial whirlwind of adjustment, I realized that my PhD training at HBRS, mentored by Burkhard Tümmler among others, had prepared me well for life as an independent scientist. Rather than merely coping in this competitive environment, I enjoyed the liberty and privilege of carving out my own research niche, while also branching into new territories, unfettered by budgetary concerns. My experimental choices were now solely dictated by what would most effectively address the questions of my projects, rather than being constrained by financial limitations or the absence of required IT structure. This marked a thrilling leap in my scientific experience and my learning curve continues to soar. I attend seminars with the leading minds in and outside my scientific niche, I engage in interdisciplinary dialogues, including deep dives into the ethical, societal, and mathematical aspects of machine learning and biotechnology. Weekly peer meetings and postdoctoral seminars serve as a constant peer review mechanism, allowing for the ongoing refinement of my work. It is demanding to scrutinize and debate the shortcomings of my research constantly, but it's even more gratifying to elevate the project's quality by recalibrating analytical and

coding strategies regularly. Moreover, for the first time in my career, Boston's collaborative environment enabled me to work with pioneers from industry, shifting my focus from a project-to-project or paper-to-paper mentality to a broader emphasis on real-world applications. Unlike in Europe where industry and academia often operate in separate orbits, in Boston, they are more integrated, facilitating a quicker transition from theoretical mathematical frameworks to practical solutions with societal and biomedical impact.

Closing Thoughts: As I look back on the first year of my postdoc experience, I am grateful for my PhD journey at HBRS and the mentorship I received. The program shaped me into a competitive problem solver by focusing on my personal development as an independent scientist. In Boston, I was then able to look more outwards, absorbing new perspectives and building a network from national and international collaborations in both academia and industry. Realizing the potential of this expanding network, I've come to understand that sustained collaborations will allow me to maintain this level of opportunity and resources, no matter where my career leads me next. So, if you're contemplating a PhD at HBRS, I encourage you to go for it. For those who have recently completed their PhD or are nearing the finish line and are unsure about what's next, consider venturing into an overseas postdoc. While it will be challenging, you are more equipped for what lies ahead than you might realize now. Earning your PhD at HBRS ensures you possess the essential skills needed to succeed in the next chapters of your professional life.

Although I did not talk about Boston's stunning surroundings, I do have two impressions to share. First, picture a turkey casually strolling down the street, keeping me company on my commute to work. Second, you'll find cautionary signs posted along Boston's beaches, alerting visitors to the potential presence of white sharks that might join you during your swim (see below).



View from abroad 2

By Thais Langer



MD/PhD program "Molecular Medicine"; final exam January 2019; current Scientific Marketing Supervisor & Content Manager, Elvessy, Paris, France

Hello from Paris

I joined the HBRS PhD program after working several jobs and studying worldwide, and I appreciated having my diverse CV chosen by the HBRS selection committee. I wanted to do my PhD in Germany, and Hannover was the ideal place - it was affordable, peaceful, and an accessible hub to travel to several places (I travel a lot!).

I was passionate about my research topic, which I strongly recommend to anyone considering a PhD. I studied

the effect of NK cell antigens in chronic rejection in solid organ transplantation at Roland Jacob's lab. It ended in 2019, right when the COVID pandemic started. However, after doing a short postdoc, I realized I wanted to shift gears and combine my varied experience and communication skills to start a career in science communication.

I created my own business with the goal of bringing together science, society, and industry. I had the opportunity to work on exciting projects, including an eBook explaining gene therapies for the lay audience with the University of Porto. My "over-communicative" personality and writing skills were finally paying off! So one thing led to another, and I eventually moved to Paris, where I work as a Science Marketing Manager for a company that started as my client. My primary expertise is inbound marketing content strategy for biotech companies.

Life in France is quite different from Germany - new language, food, and high living costs - and working in the industry is entirely distinct from academia. However, every field has its challenges, and I greatly enjoy the diversity of my current work. Paris is a very international and vibrant city with people from all over the world, which makes me feel at home.

My next goal is to share my professional journey with younger scientists and provide communication training for PhD candidates. I want to help pave the way for a future generation of scientists better prepared to communicate science - whether to publish research, enhance public trust, or share innovative technologies to advance scientific achievements. We are often so involved with research that we do not realize the importance of communication skills and the abilities we develop in academia. If you want to know more about my work and experience, feel free to connect with me on LinkedIn. I would love to hear from you!!

Final exams

In November 2022, January and June 2023, twelve students of the MD/PhD program "**Molecular Medicine**" successfully passed their final exams (Manfred Anim, Martin Bentler, Ian Bresch, Fiorella Paola Charles Cano, Sonja Groß, Fatema Hasan, Funmilola Josephine Haukamp, Christopher Jahn, Dimyana Neufeldt, Juliette Nowak, Tom Pieper, Fairouz Qasrawi, Claudio Rodriguez Gonzalez, Maximilian Schinke, Katrin Teich). The next exams are expected for November 10th, 2023.

The final exams in the PhD programs "Infection Biology" and "DEWIN" took place on January 20th, 2023 (Kris Alvarez, Matthias Bruhn, Nicola Frericks, Alina Matthaehi, Samuel Osanyinlusi, Timmy Richardo, Katarzyna Szymanska-De Wijs and Eshraq Tantawy), followed by the next ones on June 30th, 2023 (Azadeh Azadegan, Luise Krajewski, Felix Mullenge, Kodwo Appoh Odum, Sunayana Shyam Jandhyala, Tanvi Tikla, Jiayi Wang and Melina Winkler). The next final exams are scheduled for January 19th, 2024.

Award of HBRS PhD prize

October 2022

Luis M. Ferreira de Almeida (MD/PhD program Molecular Medicine)



On January 27th, 2023, nine students of the PhD Program "**Regenerative Sciences**" successfully passed their final exams: Randa Bawadi, Santoshi Biswanath Devadas, Mark-Christian Jaboreck, Khatuna

Lobjanidze, Mikhail Magdei, Ariane Nguyen, Wiebke Triebert nee Löbel, Kevin Ullmann, Rensheng Wan. On June 23rd, 2023 Andriana Stamo-poulou and Linqun Zheng successfully defended their PhD thesis; and finally Sebastian Andreas Hook on August 24th

Nathalie Fernández (January 2023) and Max Hassenstein (March 2023) recently passed their final exams in the PhD program "**Epidemiology**".

Juan Pablo Marcoleta from the PhD program "**Auditory Sciences**" successfully passed his final exam.

"Your assumptions are your windows on the world. Scrub them off every once in a while, or the light won't come in"

Isaac Asimov (1920-1992), Biochemist/Author

Announcements



Marriages: Many of our students have married recently. We know of Razan Jammal, Congratulations!



Children: There are new "HBRS babies" by Felix Adams, Alexandra Ingendoh, Razan Jammal, Caroline Mangare, Katharina Schimmel, Kristina Thamm Congratulations!

Prizes and grants

Some Alumni students were awarded important prizes for their research achievements or received grants:

Bernard Silenou (PhD program Epidemiology) was one of three awardees of the "PhD Award / Friends of HZI". The ceremony took place in June 6, 2023.

Sonja Groß (MD/PhD program) received the Guido Tarone Award at the Heart Failure Winter Meeting in Les Diablerets (HFA) as well as the Young Investigator Award at the Heart Failure Conference in Prag (ESC).

Chidiebere Awah (MD/PhD program) has received the X-seed Award of \$250,000 from the Deerfield Management and New York City Economic Development for the discovery of novel mRNA overwriting technology and its application in degrading c-MYC and ERBB2 across multiple cancers.

Chidiebere has also been awarded the 40 under 40 in Cancer as one of the top young cancer professionals in the United States-"emerging leaders and rising stars" as well as the U54 pre-pilot NIH award \$15,000 and the Center of Advanced Technology, City University of New York as a co-PI of \$32,000.

Impressum and contact:

HBRS office, OE 9117
Dr. Susanne Kruse
Carl-Neuberg-Str. 1, D-30625 Hannover
Tel. +49-(0)511-532-6011; Fax. -2611
HBRS@mh-hannover.de

Dr. Alice Rovai (PhD program Regenerative Sciences) received the publication award of the German Liver Foundation, amounting to 7500 Euro.

Shuyong Zhu (PhD Infection Biology) received 640.000 € for three years from the province and central government of China..

SAMUEL AYODEJI (PhD Infection Biology) received the Best Season Paper Award Spring 2023 of the jGfV

Katharina Schimmel (MD/PhD program) received two career development awards, one from the American Heart Association and the other one from the Parker B Francis Foundation. Both of them are for 3 years and provide her with \$0.5 million worth of funding. Based on the two awards, she was promoted to junior faculty (instructor) at Stanford.

What is...doing?

Greetings from Kenya!

I am currently working as a lecturer at South Eastern Kenya University (full-time) and Jomo Kenyatta University of Agriculture and Technology (part-time), supervising postgraduate students (8 Masters and 1 PhD). Furthermore, I am a principal investigator in the characterization of immunological profiles in COVID-19 among the African population. This research project is supported by a research grant from The World Academy of Sciences (TWAS) and the Africa-ai-Japan project (Phase 2). The research also involves collaborations with The Institute of Infectious Disease and Molecular Medicine, the University of Cape Town, and the Helmholtz Center for Infectious Research. I have applied for several research grants and am working towards becoming an independent investigator and adept mentor to upcoming researchers in Africa.

Wishing you well. Kind regards,
Caroline Mangare (Alumna MD/PhD)

If you would like to get in touch with anybody from the huge Alumni list, please contact the HBRS office. We will be happy to assist you!

There is also a HBRS LinkedIn group:
<https://www.linkedin.com/groups/2354739>

and a LinkedIn ZIB Alumni group:
<https://www.linkedin.com/in/alumni-zib-46756a16b/>

As well as a PhD RegSci LinkedIn group:
<https://www.linkedin.com/groups/9084167/>

Bank account for donations:

Please transfer the donation to the following account:
Donations:
Gesellschaft der Freunde der MHH e.V.
Commerzbank Hannover, SWIFT: COBADEFF250
IBAN DE3925040066031200300, To: 11000227, HBRS

